Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
Theravance Biopharma, Inc. logo

NASDAQ · TBPH

Theravance Biopharma, Inc.

Healthcare · Biotechnology

$17.03

Up+$0.00 (+0.00%)

Updated Oct 3, 2026, 9:13 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
895.4M
P/E ratio
54.65
Dividend yield
0.00%
52-week range
$13.08 – $21.03
Volume
10.04M
Avg. volume
424.9K

Price performance · TBPH

TBPH price history

1M range · 13 trading sessions · Daily adjusted prices

Prices through Sep 23, 2026

TBPH closed at $17.03 after 13 trading sessions, down 0.29% for the selected period.

Last close
$17.03
Period change
-0.29%
Period low
$17.01
Period high
$17.08
Daily close
View OHLC price history
TBPH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 23, 2026$17.06$17.07$17.02$17.0310.04M
Sep 22, 2026$17.04$17.08$17.03$17.036.19M
Sep 21, 2026$17.03$17.07$17.03$17.05667.3K
Sep 18, 2026$17.03$17.05$17.02$17.02683.74K
Sep 17, 2026$17.04$17.04$17.02$17.04306.99K
Sep 16, 2026$17.04$17.04$17.02$17.03461.69K
Sep 15, 2026$17.02$17.06$17.02$17.04403.74K
Sep 14, 2026$17.01$17.05$17.01$17.03243.26K
Sep 11, 2026$17.06$17.06$17.00$17.01426.8K
Sep 10, 2026$17.05$17.05$17.00$17.02333.93K
Sep 9, 2026$17.07$17.08$17.045$17.06264.27K
Sep 8, 2026$17.08$17.10$17.06$17.06251.66K
Sep 4, 2026$17.255$17.255$17.07$17.08160.55K

Latest TBPH news

The latest Smart Investors Daily articles mentioning TBPH.

Stock researchCompany · Overview

TBPH research

Overview

Company profile and research snapshot.

Company profile

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$33.50
Implied upside
—
Analysts
12
TBPH recent ratings
DateFirmRatingTarget
Jul 7, 2026HC Wainwright & Co.Neutral—
Jun 29, 2026BTIGNeutral—
Jun 29, 2026Jones TradingHold—
Apr 7, 2026B. Riley SecuritiesNeutral—
Mar 23, 2026TD CowenHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Zymeworks Completes Acquisition of Theravance Biopharma

Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By